Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 2 Compare versions History 23 Sponsors

House Committee Report — · 1.2K words Open full page ↗

89R14527 CJD-F

By: Harris, Leach, Phelan, Orr, VanDeaver,

H.B. No. 3717

Sign in to read the full text

The document summary and details above are public. The full text is available to signed-in accounts.

Create a free account Sign in

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base Floor Consideration — base rate 19%, measured from TX's completed sessions
Momentum +4 66/100 from the pace of recorded action
Time since last action -22 522 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.